Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Etoposide 31Carboplatin 30atezolizumab 17durvalumab 16Cisplatin 14Topotecan 11PM 01183 11Specimen Handling 9pembrolizumab 8Magnetic Resonance Spectroscopy 7olaparib 5Radiotherapy 5berzosertib 4anlotinib 4Paclitaxel 4Nivolumab 4Irinotecan 4Drug Therapy 4tremelimumab 3toripalimab 3tislelizumab 3Temozolomide 3Radiosurgery 3Injections 3Docetaxel 3Biopsy 3Bevacizumab 3AMG 757 3sacituzumab govitecan 2monalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × 18-O-demethylcervinomycin A2 × 90 days × Clear all
NCT07296809 2026-05-08

SKB500 Combinations in Patients With Small Cell Lung Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
80 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡